Tissue distribution of 131I-labelled epidermal growth factor in the pig visualized by dynamic scintigraphy

in Journal of Endocrinology
Authors:
L Vinter-Jensen
Search for other papers by L Vinter-Jensen in
Current site
Google Scholar
PubMed
Close
,
J Frøkiær
Search for other papers by J Frøkiær in
Current site
Google Scholar
PubMed
Close
,
P E Jørgensen
Search for other papers by P E Jørgensen in
Current site
Google Scholar
PubMed
Close
,
J Marqversen
Search for other papers by J Marqversen in
Current site
Google Scholar
PubMed
Close
,
M Rehling
Search for other papers by M Rehling in
Current site
Google Scholar
PubMed
Close
,
E Z Dajani
Search for other papers by E Z Dajani in
Current site
Google Scholar
PubMed
Close
, and
E Nexø
Search for other papers by E Nexø in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Abstract

We visualized the metabolism of intravenously injected 131I-labelled epidermal growth factor in the pig using dynamic scintigraphy combined with repetitive samplings of blood, urine and bile. The labelled peptide was recognized in the samples by means of immunoprecipitation and high pressure liquid chromatography. The plasma elimination was extremely rapid, and it was described with a triexponential equation, C(t)=A*e −α*t+B*e −β*t+ C*e −γ*t. The first two exponentials denoted the distribution phase, and the third the elimination phase. T1/2α ranged from 0·4–0·7 min, T1/2β from 2·0–2·2 min and T1/2γ from 53·3–97·6 min. Concomitant with the rapidly declining plasma concentration, the gamma camera visualized the uptake by the liver and the kidneys. The liver was the principal organ for clearance and degradation of the labelled peptide, but only 0·12–0·30% of the injected dose was excreted into the bile. The renal uptake and the urinary excretion accounted for 6·6–13·0 and 2·5–4·9% of the given dose, respectively.

Journal of Endocrinology (1995) 144, 5–12

 

  • Collapse
  • Expand